2 news items
Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results
ABSI
21 Mar 24
an immunosuppressive cytokine and is believed to stimulate innate immune response. ABS-301 is being evaluated for a broad applicability to a variety of oncology
The Analyst Landscape: 4 Takes On Absci
ABSI
6 Mar 24
their response to recent developments related to Absci. This offers insight into analysts' perspectives on the current state of the company
- Prev
- 1
- Next